Meeting
2024 ASCO Genitourinary Cancers Symposium
Describing the genomic landscape of bladder cancer histologic subtypes.
Authors
Rafee Talukder
Baylor College of Medicine, Houston, TX
Rafee Talukder , Rachel Berg , Minxuan Huang , Vanessa M. Nepomucino , Melissa Conrad Stoppler , Dimitrios Makrakis , Aihua Edward Yen , Martha P. Mims , Seth P. Lerner , Solomon L. Woldu , Yair Lotan , Evan Y. Yu , Ali Raza Khaki , Jeanny B. Aragon-Ching , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 680)
DOI
10.1200/JCO.2024.42.4_suppl.680
Abstract #
680
Poster Bd #
L2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod
Poster
2022 ASCO Annual Meeting
Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).
First Author: Maroun Bou Zerdan
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2021 Genitourinary Cancers Symposium
Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).
First Author: Gennady Bratslavsky